EFM
RCKT icon

E Fund Management’s Rocket Pharmaceuticals RCKT Stock Holding History

E Fund Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,751
Closed -$63.5K – 512
2026
Q1 		$63.5K Buy
+17,751
New +$70.5K ﹤0.01% 484
2025
Q2 		– Sell
-14,567
Closed -$97.2K – 421
2025
Q1 		$97.2K Buy
14,567
+3,513
+32% +$34.7K ﹤0.01% 383
2024
Q4 		$139K Buy
+11,054
New +$166K 0.01% 375
2024
Q2 		– Sell
-15,549
Closed -$419K – 364
2024
Q1 		$419K Buy
15,549
+4,352
+39% +$124K 0.03% 202
2023
Q4 		$336K Sell
11,197
-1,215
-10% -$26.8K 0.02% 219
2023
Q3 		$254K Sell
12,412
-120
-1% -$2.18K 0.02% 223
2023
Q2 		$249K Sell
12,532
-4,469
-26% -$90.3K 0.02% 244
2023
Q1 		$291K Buy
17,001
+1,601
+10% +$31.3K 0.02% 229
2022
Q4 		$301K Sell
15,400
-178
-1% -$3.28K 0.03% 235
2022
Q3 		$249K Buy
+15,578
New +$243K 0.02% 266

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

E Fund Management's RCKT Position: Q2 2026 in Review

E Fund Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 17,751 shares — an estimated $63.5K sold.

E Fund Management first reported a position in RCKT in Q3 2022 and held it in 10 quarters. The position peaked at $419K in Q1 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • E Fund Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • E Fund Management sold 17,751 Rocket Pharmaceuticals shares in Q2 2026, an estimated $63.5K.
  • E Fund Management first reported a position in Rocket Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • E Fund Management's Rocket Pharmaceuticals position peaked at $419K in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.